Polarized immune responses differentially regulate cancer development
- 19 March 2008
- journal article
- research article
- Published by Wiley in Immunological Reviews
- Vol. 222 (1) , 145-154
- https://doi.org/10.1111/j.1600-065x.2008.00600.x
Abstract
Summary: Tumor‐associated immune responses assert varied responses toward developing neoplasms that can either act to eradicate malignant cells via engagement of potent cytotoxic programs or alternatively enhance tumor growth through release of multifunctional pro‐tumor mediators. Seemingly paradoxical, these disparate activities reflect a continuum of polarization (or activation) states possible for distinct leukocyte subsets that demonstrate tissue, organ, and tumor selectivity. Herein, we review clinical and experimental studies investigating cellular and molecular mechanisms utilized by neoplastic tissues to alternatively polarize immune responses that favor either pro‐ or anti‐tumor immunity.Keywords
This publication has 93 references indexed in Scilit:
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Toll-like receptors in systemic autoimmune diseaseNature Reviews Immunology, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005
- Toll-like receptor signallingNature Reviews Immunology, 2004
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- Inflammation and cancerNature, 2002
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- The Hallmarks of CancerCell, 2000